GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 GAAP Diluted EPS of $0.27 for the Fourth Quarter o.
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -
- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the.